What happened

Shares of Axon Enterprise (NASDAQ:AXON), the maker of TASER stun guns and body cameras, moved higher last month, gaining 17% according to S&P Global Market Intelligence. The company, which also runs a cloud-based data management service for law enforcement, benefited from an analyst upgrade, as well as hopes for its upcoming first-quarter earnings report.

The chart below shows the stock's upward trend over the month. 

AAXN Chart

AAXN data by YCharts.

So what 

Axon's best day of the month came on April 8 as the stock rose 4.5%, following a similar gain the session before after the stock got an upgrade from Raymond James. 

An officer wearing an Axon body camera writes a ticket.

Image source: Getty Images.

Analyst Brian Gesuale lifted his rating from outperform to strong buy but maintained his price target at $79. Gesuale also said the company's stock could hit $100 a share by 2021, arguing that the power of the company's growing subscriber base is being underestimated. He also said that the business is still being valued like a hardware company, even though its emerging cloud business could deliver significant profit growth, and noted that software sales made up just 2% of revenue in 2014, compared to 20% in 2018, a sign of the shift in the overall business.

That was the biggest news driving Axon shares higher last month, but the company also announced further expansions including in Kingston, Ontario and other Canadian communities and improvements in its product lineup including Axon Performance, which helps agencies measure officer performance and identify training needs.

Now what 

Investors are also looking ahead to Axon's earnings report coming out on May 9 but hoping for a different result than the sell-offs that followed the last two earnings reports. Analysts have a low bar, expecting revenue to grow 9.3%, to $110.61, and for earnings per share to fall from $0.29 to $0.16. Axon said previously that it expects revenue growth to pick up in the second half of the year as shipments of the TASER 7 and Axon Body 3 increase, so investors should keep on eye on guidance, as well, when the report comes out.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.